BigSpeak is your one-stop source for diversity speakers, leadership keynote speakers, teamwork motivational speakers, and all of the best inspirational speakers. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA Jr. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection. J Clin Oncol. Keywords provided by Merck Sharp & Dohme Corp.: Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Why Should I Register and Submit Results? Convert .KEY to .PPT or .PPTX files online using CloudConvert! J Clin Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr, Italiano A, Kao S, Piha-Paul SA, Delord JP, McWilliams RR, Fabrizio DA, Aurora-Garg D, Xu L, Jin F, Norwood K, Bang YJ. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. 2019 Feb 1;37(4):318-327. doi: 10.1200/JCO.2018.78.2276. Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK. Cancer. Has had an allogenic tissue/solid organ transplant. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced NonâSmall-Cell Lung Cancer With PD-L1 Tumor Proportion Score ... advanced NSCLC without EGFR/ALK aber-rations, despite crossover from ⦠Lancet Oncol. Epub 2017 Nov 2. J Clin Oncol. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. The study hypothesis is that administration of pembrolizumab to participants with some types of solid tumors will result in a clinically meaningful response rate. 2017 Dec 20;35(36):4050-4056. doi: 10.1200/JCO.2017.73.3675. DLP chipsets can control high power NIR lasers to enable printing, marking and selective laser sintering (SLS) additive manufacturing. Rugo HS, Delord JP, Im SA, Ott PA, Piha-Paul SA, Bedard PL, Sachdev J, Le Tourneau C, van Brummelen EMJ, Varga A, Salgado R, Loi S, Saraf S, Pietrangelo D, Karantza V, Tan AR. Study record managers: refer to the Data Element Definitions if submitting registration or results information. Please remove one or more studies before adding more. Has received a live vaccine within 30 days of planned start of study medication. PFS is defined as the time from allocation to the first documented disease progression according to RECIST 1.1 as assessed by independent central radiologic review, or death due to any cause, whichever occurs first. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. 2018 Jun 15;24(12):2804-2811. doi: 10.1158/1078-0432.CCR-17-3452. Genetic and Rare Diseases Information Center, Merck Oncology Clinical Trials Information. Keywords provided by Merck Sharp & Dohme Corp.: Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Why Should I Register and Submit Results? Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Individual Participant Data (IPD) Sharing Statement: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf, http://engagezone.msd.com/ds_documentation.php. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Mehnert JM, Varga A, Brose MS, Aggarwal RR, Lin CC, Prawira A, de Braud F, Tamura K, Doi T, Piha-Paul SA, Gilbert J, Saraf S, Thanigaimani P, Cheng JD, Keam B. KEY to PDF Converter. [Epub ahead of print]. 2018 Nov;41(11):1083-1088. doi: 10.1097/COC.0000000000000429. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Cancer. Responses will be determined by independent central radiologic review, with confirmatory assessment as required per RECIST 1.1. Keynote began life in 2002 as an internal Apple tool developed for Steve Jobs to help him present at MacWorld. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. Individual Participant Data (IPD) Sharing Statement: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf, http://engagezone.msd.com/ds_documentation.php, Best Overall Response Using Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) [ Time Frame: Up to 24 months ], Progression Free Survival (PFS) [ Time Frame: Up to 24 months ], Overall Survival (OS) [ Time Frame: Up to 24 months ], Duration of Response (DOR) in Participants Who Achieve Partial Response (PR) or Better [ Time Frame: Up to 24 months ], Histologically or cytologically documented locally-advanced and/or metastatic solid malignancy that is incurable, and has failed prior standard therapy or for which standard therapy is not appropriate, Have measurable disease based on Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1), Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1, Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication, Male participants of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study medication through 120 days after the last dose of study medication, Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment, Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment, Prior anti-cancer therapy with a monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not recovered from adverse events due to mAbs administered more than 4 weeks earlier, Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks (12 weeks for measurable sites of central nervous system [CNS] disease) prior to study Day 1 or not recovered from adverse events due to a previously administered agent, Known additional malignancy that is progressing or requires active treatment excepting basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer, Known active CNS metastases and/or carcinomatous meningitis, Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e. Ott PA, Elez E, Hiret S, Kim DW, Morosky A, Saraf S, Piperdi B, Mehnert JM. Keynote address delivered at the European Congress of Behavioural and Cognitive Therapies, London, September 24, 1993 ... questions to ask," more advanced therapists were quite aware that these generic questions were not enough. For general information, Learn About Clinical Studies. Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J. Keynote Speakers, Business Speakers and Motivational Speakers â use search filters below to find the best keynote speakers and create personalized MyCatalogs. 2017 May;18(5):623-630. doi: 10.1016/S1470-2045(17)30169-9. Epub 2020 Jan 24. Participants must not have melanoma or NSCLC. Pembrolizumab prolongs overall survival and has a favourable benefit-to-risk profile in patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. 2017 Dec 28;12(12):e0189848. Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma. $ Virtual Registration Fee: In-Person Conference Registration Fee: Studies a U.S. FDA-regulated Drug Product: Studies a U.S. FDA-regulated Device Product: Objective Response Rate (ORR) [ Time Frame: Up to approximately 2 years ], Duration of Response (DOR) [ Time Frame: Up to approximately 2 years ], Progression Free Survival (PFS) [ Time Frame: Up to approximately 2 years ], Overall Survival (OS) [ Time Frame: Up to approximately 2 years ], Biliary Adenocarcinoma (gallbladder or biliary tree (intrahepatic or extrahepatic cholangiocarcinoma) except Ampulla of Vater cancers), Neuroendocrine Tumors (well- and moderately-differentiated) of the lung, appendix, small intestine, colon, rectum, or pancreas, Endometrial Carcinoma (sarcomas and mesenchymal tumors are excluded), Salivary Gland Carcinoma (sarcomas and mesenchymal tumors are excluded), Any advanced solid tumor, with the exception of colorectal carcinoma (CRC), which is Microsatellite Instability (MSI)-High (MSI-H) OR, Any advanced solid tumor (including Colorectal Carcinoma [CRC]) which is Mismatch Repair Deficient (dMMR)/MSI-H in participants from mainland China who are of Chinese descent. Keynote is a multi-syllabus ELT course for working adults and students that uses inspirational TED Talks to teach English. 2021 Jan 26. doi: 10.1002/cncr.33378. Mehnert JM, Bergsland E, O'Neil BH, Santoro A, Schellens JHM, Cohen RB, Doi T, Ott PA, Pishvaian MJ, Puzanov I, Aung KL, Hsu C, Le Tourneau C, Hollebecque A, Élez E, Tamura K, Gould M, Yang P, Stein K, Piha-Paul SA. O'Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, Ejadi S, Piha-Paul SA, Stein MN, Abdul Razak AR, Dotti K, Santoro A, Cohen RB, Gould M, Saraf S, Stein K, Han SW. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. Talk with your doctor and family members or friends about deciding to join a study. Gynecol Oncol. Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, van Brummelen E. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. U.S. Department of Health and Human Services, The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. Read press releases, get updates, watch video and download images. Epub 2018 Mar 20. 2017 May 1;28(5):1036-1041. doi: 10.1093/annonc/mdx029. 2018 Jan 1;36(1):61-67. doi: 10.1200/JCO.2017.74.9846. 2017 Dec 20;35(36):4035-4041. doi: 10.1200/JCO.2017.74.5471. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) Participants receive pembrolizumab 200 mg intravenously on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years of treatment). Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. This study will assess the efficacy and safety of pembrolizumab (MK-3475) administered to participants with incurable advanced biomarker-positive solid tumors that have not responded to current therapy or for which current therapy is not appropriate. Thanks to our advanced conversion technology the quality of the output PowerPoint document will be exactly the same as if it was saved through the latest iWork suite from Apple. A Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. J Clin Oncol. DOR, defined in the subset of participants with a CR or PR, based on RECIST 1.1 as assessed by independent central radiologic review, as the time from first documented evidence of CR or PR until the first documented sign of disease progression or death due to any cause, whichever occurs first. Choosing to participate in a study is an important personal decision. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. (Clinical Trial), Phase IB Study of Pembrolizumab (MK-3475) in Subjects With Select Advanced Solid Tumors, 18 Years and older (Adult, Older Adult). Epub 2018 Dec 13. Censoring will be performed using the date of last known contact for those who are alive at the time of analysis. The percentage of participants who experience a CR or PR based on modified RECIST 1.1 will be presented. The first version was made available to the public in 2003 as Keynote 1.0 and was designed to compete with Microsoft's Powerpoint presentation software which formed part of Microsoft Office. To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. (Clinical Trial), A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158), 18 Years and older (Adult, Older Adult), Call for Information (Investigational Site 0018), Call for Information (Investigational Site 0202), Los Angeles, California, United States, 90033, Call for Information (Investigational Site 0017), Los Angeles, California, United States, 90048, Call for Information (Investigational Site 0015), Call for Information (Investigational Site 0011), Baltimore, Maryland, United States, 21231, Call for Information (Investigational Site 0005), Rockville, Maryland, United States, 20850, Call for Information (Investigational Site 0207), Boston, Massachusetts, United States, 02114, Call for Information (Investigational Site 0010), Boston, Massachusetts, United States, 02215, Call for Information (Investigational Site 0209), Call for Information (Investigational Site 0008), New Brunswick, New Jersey, United States, 08903, Call for Information (Investigational Site 0004), Contact: Australian Medical Information Centre 61 2 8988 8428, Contact: Medical Information Centre Centre d'information medicale Merck Canada Inc. 514-428-8600 / 1-800-567-2594, Contact: Francesca Carvajal 57 1219109011090, Contact: German Medical Information Center 49 800 673 673 673, Contact: Barbara Capaccetti 39 06361911, Contact: Japan Call Center 81-3-6272-1957, Contact: Jongho Ahn 82-2-331-2000 2015, Contact: Caroline Doornebos 31 23 515 3362, Contact: Tony Johansson 47 32 20 75 20, Contact: Tatiana Serebriakova 74959167100, EXT.366, Contact: Lourdes Lopez-Bravo (0034) 913210654. ⢠Virtual Keynote Address ⢠Up to 21 hours CPE credit ... (Advanced) $1,950 $ Up to 10 firm attendees (Premium) $3,050 $ Less Early Bird Discount per package (3/31/21) -$100 per package. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. Clin Cancer Res. Choosing to participate in a study is an important personal decision. 2019 Mar 4;19(1):196. doi: 10.1186/s12885-019-5380-3. Featuring remarkable people communicating passionately and persuasively, TED Talks provide the ELT classroom with inspiring ideas and an unparalleled source of authentic language input. PATIENTS AND METHODS In this open-label, phase III study, we randomly assigned (1:1) 628 patients with advanced/metastatic squamous cell carcinoma or adenocarcinoma of the esophagus, that progressed after one prior therapy, to pembrolizumab 200 mg ⦠You have reached the maximum number of saved studies (100). Microsoft Ignite | Microsoftâs annual gathering of technology leaders and practitioners delivered as a digital event experience this March. Note: The appearance of one or more new lesions is also considered PD. J Clin Oncol. Epub 2020 Sep 10. Participants who are alive, have not progressed, have not initiated new anti-cancer treatment, and have not been determined to be lost to follow-up are considered ongoing responders at the time of analysis. Epub 2019 Apr 3. Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Near-infrared (NIR) products are optimized for 700 to 2500 nm. Please remove one or more studies before adding more. Epub 2018 Dec 3. I didn't simply ask these questions over and 2018 Aug 1;29(8):1807-1813. doi: 10.1093/annonc/mdy232. PLoS One. 2017 Dec 1;35(34):3823-3829. doi: 10.1200/JCO.2017.72.5069. Frenel JS, Le Tourneau C, O'Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas S, Saraf S, Rangwala R, Varga A. is not considered a form of systemic treatment, Has evidence of interstitial lung disease or a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis, Active infection requiring systemic therapy, Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial, Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment, Has previously participated in any other pembrolizumab (MK-3475) trial, or received prior therapy with an anti-PD-1, anti-PD-L1, and anti-PD-L2 (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways), Known history of human immunodeficiency virus (HIV). Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. Epub 2017 May 10. Cancer. Hansen AR, Massard C, Ott PA, Haas NB, Lopez JS, Ejadi S, Wallmark JM, Keam B, Delord JP, Aggarwal R, Gould M, Yang P, Keefe SM, Piha-Paul SA. 2019 Feb;152(2):243-250. doi: 10.1016/j.ygyno.2018.11.017. Epub 2017 Aug 24. doi: 10.1371/journal.pone.0189848. Epub 2017 Nov 8. J Clin Oncol. J Clin Oncol. 2020 Jul 1;126(13):3021-3030. doi: 10.1002/cncr.32883. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02054806. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Study record managers: refer to the Data Element Definitions if submitting registration or results information. Strosberg J, Mizuno N, Doi T, Grande E, Delord JP, Shapira-Frommer R, Bergsland E, Shah M, Fakih M, Takahashi S, Piha-Paul SA, O'Neil B, Thomas S, Lolkema MP, Chen M, Ibrahim N, Norwood K, Hadoux J. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. Epub 2020 Apr 22. eCollection 2017. Epub 2020 Apr 22. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, Puzanov I, Mehnert JM, Aung KL, Lopez J, Carrigan M, Saraf S, Chen M, Soria JC. OR. Listing a study does not mean it has been evaluated by the U.S. Federal Government. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. The dosing regimen for this cohort will be 400 mg every 6 weeks (Q6W) for up to 18 administrations (up to approximately 2 years of treatment). Ann Oncol. Am J Clin Oncol. Any advanced solid tumor that has failed at least one line of therapy and is TMB-H (≥10 mut/Mb, F1CDx assay), excluding dMMR/MSI-H tumors. Read our, ClinicalTrials.gov Identifier: NCT02054806, Interventional
2020 May 1;26(9):2124-2130. doi: 10.1158/1078-0432.CCR-19-3014. Varga A, Piha-Paul S, Ott PA, Mehnert JM, Berton-Rigaud D, Morosky A, Yang P, Ruman J, Matei D. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. 2019 Jun 10;37(17):1470-1478. doi: 10.1200/JCO.18.01265. Information provided by (Responsible Party): In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475). Progression of tumor or intolerance to therapies known to provide clinical benefit. Cohen RB, Delord JP, Doi T, Piha-Paul SA, Liu SV, Gilbert J, Algazi AP, Damian S, Hong RL, Le Tourneau C, Day D, Varga A, Elez E, Wallmark J, Saraf S, Thanigaimani P, Cheng J, Keam B. Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. Ann Oncol. The trial protocol is available in the appendix. Amongst many others, we support PDF, PPTX, PPT, ODP. OS is presented. Epub 2020 Sep 10. KEYNOTE-426 is an ongoing, phase 3, randomised, open-label trial in treatment-naive advanced renal cell carcinoma, being done in 129 sites (hospitals and cancer centres) in 16 countries (appendix pp 2â6). CloudConvert is an online document and presentation converter. Keynote For Windows free download - Apple Keynote, Windows Media Player, Viber for Windows, and many more programs ClinicalTrials.gov Identifier: NCT02628067, Interventional
with use of disease modifying agents, corticosteroids or immunosuppressive drugs). The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. J Clin Oncol. Clin Cancer Res. Participants with unknown or missing response information will be treated as non-responders. OS was defined as the time from randomization to death due to any cause. 2020 Jul 1;126(13):3021-3030. doi: 10.1002/cncr.32883. Lancet Oncol. For general information, Learn About Clinical Studies. Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S, Pruitt SK, Leary A. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02628067. Epub 2017 Aug 16. BigSpeak Speakers Bureau works with top virtual keynote speakers such as Marc Randolph, Molly Bloom, Magic Johnson, Matthew Luhn, James Clear, and other top business keynote speakers. 2017 Aug 1;35(22):2535-2541. doi: 10.1200/JCO.2017.72.5952. You have reached the maximum number of saved studies (100). (CRC participants will have a histologically proven locally advanced unresectable or metastatic CRC which is dMMR/MSI-H that has received 2 prior lines of therapy.) Click on the links below to download the following samples from Keynote Proficient:. There is no limit to the number of prior treatment regimens, Can supply tumor tissue for study analyses (dependent on tumor type), Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale within 3 days prior to first dose of pembrolizumab, Female participants of childbearing potential must be willing to use adequate contraception for the course of the study through 120 days after the last dose of study treatment, Male participants with partners of must childbearing potential must be willing to use adequate contraception for the course of the study through 120 days after the last dose of study treatment, Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study treatment, Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment, Active autoimmune disease that has required systemic treatment in the past 2 years, Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not recovered from an adverse event caused by mAbs administered more than 4 weeks earlier, Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks of study Day 1 or not recovered from adverse events caused by a previously administered agent, Known additional malignancy within 2 years prior to enrollment with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers, Known active central nervous system (CNS) metastases and/or carcinomatous meningitis, Has known glioblastoma multiforme of the brain stem, History of non-infectious pneumonitis that required steroids or current pneumonitis, Active infection requiring systemic therapy, Known psychiatric or substance abuse disorders that would interfere with the participant's ability to cooperate with the requirements of the study, Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment, Previously participated in any other pembrolizumab (MK-3475) study, or received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-Ligand 1 (anti-PD-L1), anti-PD-Ligand 2 (anti-PD-L2), or any other immunomodulating mAb or drug specifically targeting T-cell co-stimulation or checkpoint pathways, Known history of Human Immunodeficiency Virus (HIV), Received live vaccine within 30 days of planned start of study treatment, Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients, Known history of active tuberculosis (TB, Bacillus tuberculosis). Epub 2017 Mar 11.